Last edition
News about
NICO Corporation Unveils Myriad SPECTRA System for Advanced Neurosurgery
This technology promises enhanced visualization and precision in tumor and clot removal, marking a notable advancement in neurosurgical capabilities.
Cartessa Aesthetics Launches PHYSIQ 360, Redefining Non-Invasive Body Contouring
PHYSIQ 360 is engineered to tackle the persistent challenges individuals face in achieving their desired body goals.
Alaffia Health Raises USD 10 Mn to Supercharge Health Plan Operations With Generative AI
Alaffia Health announced USD 10 Mn in Series A funding, bringing its total amount of capital raised to USD 17.6 Mn.
CureVac Welcomes Thaminda Ramanayake as New Chief Business Officer
CureVac has announced the appointment of Thaminda Ramanayake as the new Chief Business Officer.
Surgeons at NYU Langone Health performed the first-ever combined mechanical heart pump and gene-edited pig kidney transplant surgery in a 54-year-old woman with heart and kidney failure—a confluence of advances that showcase the possibility and hope of modern medicine.
Bormioli Pharma's EcoPositive Line Achieves 45 Percent Sustainable Materials Utilization
The company has made significant strides in increasing the share of sustainable materials in its products, nearing its 50 percent target by 2025 with 45 percent achieved in 2023.
Tetra Pharm Technologies and Glysious to Develop Transdermal Combination Drugs
Tetra Pharm Technologies has joined forces with Glysious, to develop a ground-breaking transdermal drug delivery system complementing several of Tetra Pharm Technologies' pipeline candidates.
Lupin Lyfe Platform Secures Class C Medical Device License from CDSCO
Lupin Digital Health has announced that its Lyfe platform has received approval as a Class C Medical Device from the Central Drugs Standard Control Organization (CDSCO).
PRISM BioLab and Ono Pharmaceutical Enters into Joint Research and Licensing Agreement
Under the terms of the agreement, PRISM and Ono will collaborate closely to create a development candidate for Ono's oncology target, harnessing the cutting-edge PepMetics® technology pioneered by PRISM.
Evotec OAI Partners with Taisho Pharmaceutical to Accelerate Drug Discovery
Evotec OAI has entered into a drug discovery collaboration with Taisho Pharmaceutical Co., Ltd. Tokyo, Japan.
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy